Sanofi’s Aubagio Wins Final Approval From U.K. Cost Agency NICE

Sanofi’s multiple sclerosis drug Aubagio won final approval from the U.K.’s health-cost agency, allowing access to a market in which it will compete with Novartis AG’s Gilenya.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.